Absci News - September 17, 2026
🟢 Absci is trading 16.6% up today after encouraging ABS-201 safety data
Absci is trading at $9.38, up 16.60%, after interim Phase I/II data for ABS-201 showed no serious adverse events. - September 16 Morgan Stanley conference...
Absci's AI-Designed Hair-Loss Drug Clears a Safety Hurdle — But Can a Company Burning $100M a Year Survive Long Enough to Prove It Works?
Shares of Absci Corp jumped 9.8% to $8.83 after CEO Sean McClain presented updated safety results from the company's lead hair-loss drug at the Morgan Stanley...
🟢 Absci is trading 9.83% up today after encouraging interim ABS-201 Phase I/II results
Absci is trading 9.83% up now at $8.83 after presenting encouraging interim ABS-201 Phase I/II results. - No serious adverse events were reported among 32...
Absci reports safe hair loss drug results, targeting $25 billion market
Absci Corporation presented interim Phase I/II data for its hair-loss treatment, ABS-201, at the Morgan Stanley Global Healthcare Conference. The study...